Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

Area of Science:

• Orthopedics
• Genetics
• Pharmacology

Background:

• Osteogenesis imperfecta (OI) is a genetic bone disorder causing osteopenia and fractures, primarily in children.
• Current bisphosphonate treatments for pediatric OI show limited efficacy on long-bone fracture rates.
• Novel anabolic therapies are needed to enhance bone mass and strength in OI patients.

Purpose of the Study:

• To investigate the efficacy of Sclerostin antibody (Scl-Ab) therapy in a mouse model of Osteogenesis imperfecta (OI).
• To assess the anabolic potential of Scl-Ab in stimulating osteoblasts and improving bone parameters in OI.
• To evaluate the impact of Scl-Ab on bone mass, fragility, and tissue mineralization in OI.

Main Methods:

• Utilized a knock-in mouse model heterozygous for a typical OI-causing Gly→Cys substitution in col1a1.
• Administered Scl-Ab therapy for two weeks to OI model mice and wild-type (WT) controls.
• Assessed bone formation, bone mass, long-bone fragility, and tissue mineralization using image-guided nanoindentation.

Main Results:

• Two weeks of Scl-Ab therapy significantly stimulated osteoblast bone formation in both OI and WT mice.
• Scl-Ab treatment led to improved bone mass and reduced long-bone fragility in the OI mouse model.
• No alterations in local tissue mineralization dynamics were observed with Scl-Ab therapy.

Conclusions:

• Short-term Scl-Ab therapy demonstrates potent anabolic effects in osteoblasts with a typical OI-causing collagen mutation.
• Scl-Ab represents a potential novel therapeutic strategy for increasing bone mass and reducing fractures in pediatric OI.
• The anabolic mechanism of Scl-Ab contrasts with the antiresorptive effects of current OI treatments.